The FDA has issued a warning to
healthcare providers that it does not recommend co-administering
malaria meds chloroquine or hydroxychloroquine with Gilead Sciences’
(NASDAQ:GILD) remdesivir for COVID-19 patients since they may compromise the antiviral effect of the latter.
The agency says it is not aware of any instances
in the field of this reduced activity but is continuing to “evaluate all
data” related to remdesivir.
Earlier today, the FDA rescinded emergency use authorization of the malaria drugs for COVID-19.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.